Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.
Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 147, 100, 8, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 7 and 3 molecules, respectively.
Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aadi Bioscience Inc
Ability Pharmaceuticals SL
ABL Bio Inc
Abpro Corp
Acrivon Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Agenus Inc
Akeso Inc
Alaunos Therapeutics Inc
Alkermes Plc
Allarity Therapeutics Inc
Alligator Bioscience AB
Almac Discovery Ltd
Alphamab Oncology
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
Amgen Inc
Aminex Therapeutics Inc
Amphivena Therapeutics Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Apollomics Inc
Arch Oncology Inc
Arcus Biosciences Inc
Ascenta Therapeutics Inc
AstraZeneca Plc
Bantam Pharmaceutical LLC
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bellicum Pharmaceuticals Inc
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioAtla Inc
BioMed Valley Discoveries Inc
BioNTech SE
Biosion Inc
Biosplice Therapeutics Inc
Biotheus Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Byondis BV
Calithera Biosciences Inc
CanBas Co Ltd
Carrick Therapeutics Ltd
Celon Pharma SA
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
Clovis Oncology Inc
Coherent Biopharma
Compugen Ltd
Context Therapeutics Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Elucida Oncology Inc
ENB Therapeutics LLC
EpimAb Biotherapeutics Inc
Esperas Pharma Inc
EstryX Pharma Ltd
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
Genelux Corp
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
Gradalis Inc
Greenfire Bio LLC
GSK plc
Guangzhou Yinming Biomedical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
Idience Co Ltd
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunocore Limited
ImmunoGen Inc
Immvira Co Ltd
IMPACT Therapeutics Inc
Imunon Inc
Imvax Inc
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
Inspirna Inc
Instil Bio Inc
iTeos Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
L&L Biopharma Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
LegoChem Biosciences Inc
Light Chain Bioscience
MedGene Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
MorphoSys AG
NeoTX Therapeutics Ltd
Netris Pharma SAS
NextCure Inc
Northlake International LLC
Novartis AG
Novita Pharmaceuticals Inc
Nurix Therapeutics Inc
Nuvation Bio Inc
Nuvectis Pharma Inc
Olema Pharmaceuticals Inc
OncoQuest Inc
OncoResponse Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Otsuka Pharmaceutical Co Ltd
Pano Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Pionyr Immunotherapeutics Inc
Portage Biotech Inc
Precision Biologics Inc
Prelude Therapeutics Inc
PRISM Pharma Co Ltd
ProfoundBio Suzhou Co Ltd
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Qurient Co Ltd
RemeGen Co Ltd
Repare Therapeutics Inc
Rhizen Pharmaceuticals SA
Salarius Pharmaceuticals Inc
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Shandong Boan Biotechnology Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Splash Pharmaceuticals Inc
SpringWorks Therapeutics Inc
Sutro Biopharma Inc
Suzhou Maximum Bio-tech Co Ltd
Suzhou Neupharma Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
SynOx Therapeutics Ltd
Taiho Pharmaceutical Co Ltd
TCR Cure Biopharma Technology Co Ltd
Tempest Therapeutics Inc
Theratechnologies Inc
TORL Biotherapeutics LLC
Treadwell Therapeutics Inc
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Tyra Biosciences Inc
Verastem Inc
Vincerx Pharma Inc
Vyriad Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Xencor Inc
Xynomic Pharmaceuticals Holdings Inc
Y-Biologics Inc
Zymeworks Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.